Emily Jashinsky

One bystander was struck, and the suspect was killed by officers returning fire.

Here, the president.

Former Attorney General Pam Bondi revealing she has been diagnosed with thyroid cancer, telling CNN she received the diagnosis after leaving the DOJ last month.

Bondi says she is now in treatment and underwent surgery, telling the outlet she is still recovering but, quote, doing well.

The thyroid is a small endocrine gland at the front of the neck, producing hormones that help regulate metabolism, heart rate, body temperature, and other functions.

According to the National Cancer Institute, thyroid cancer accounts for roughly 45,000 new cases a year in the U.S., with a 98% five-year survival rate.

Bondi's diagnosis coming just weeks after President Trump removed her as attorney general amid frustration from the president, especially relating to her handling of the Epstein files.

At the time, President Trump posting to Truth Social that Bondi would be moving into a, quote, much-needed and important private sector role, with details to come later.

But Axios now reporting Bondi will return to the administration, President Trump appointing her to the Presidential Council of Advisors on Science and Technology, a panel of experts focused on the impact of emerging technologies, like AI, on American workers.

The panel, chaired by David Sachs, and includes major tech figures such as Meta CEO Mark Zuckerberg and Oracle co-founder Larry Ellison.

Bondi expected to serve as a liaison between the federal government and the executives advising the White House on technology policy.

Vice President J.D.

Vance releasing a statement, quote, Bondi is also scheduled to appear Friday before the House Oversight Committee as part of its Jeffrey Epstein probe.

Coming up, new research suggesting weight loss drugs like Ozempic could do much more than help people lose weight.

And NASA mapping out the next steps toward putting astronauts back on the moon.

Promising new studies suggesting popular weight loss and diabetes drugs may be linked to slower progression in four major cancers, breast, colorectal, lung, and liver cancer.

GLP-1 drugs, including semiglutide and terzepatide, are best known through brand names like Ozempic, Wegovi, and Manjaro.

Cleveland Clinic researchers analyzing data from more than 12,000 patients with stage 1 through stage 3 solid tumors, comparing patients who started GLP-1 medications after their cancer diagnosis with similar patients taking another class of diabetes drugs known as gliptins.

The study finding patients taking GLP-1s were significantly less likely to see their cancer progress to stage 4 disease.

The largest reduction seen in non-small cell lung cancer, where GLP-1 users were about 50% less likely to see their cancer spread to other parts of the body compared with patients taking gliptins.